| Cat. No. |
Product Name |
Information |
| PC-21900 |
CEP-33779
JAK2 inhibitor
|
CEP-33779 (CEP33779) is a potent, selective, and orally bioavailable inhibitor of JAK2 with IC50 of 1.3 nM, 65-fold selective over JAK3. |
| PC-21734 |
Lepzacitinib
JAK1/3 inhibitor
|
Lepzacitinib (ATI-1777) is a potent, selective and ATP-competitive JAK1/3 inhibitor with IC50 of 1.5/3.6/7.1/19.0 nM for JAK1/JAK2/JAK3/TYK2, respectively. |
| PC-21596 |
JNJ-64251330
JAK inhibitor
|
Lorpucitinib (JNJ-64251330) is potent, selective and orally bioavailable pan-JAK inhibitor with IC50 of 0.37/8.6/92/7.4 nM for JAK1/JAK2/JAK3/Tyk2 respectively. |
| PC-21425 |
WHI-P131
JAK3 inhibitor
|
WHI-P131 (JANEX-1) is a potent and selective JAK3 inhibitor with Ki of 2.3 uM and IC50 of 78 uM, with no activity agianst JAK1 and JAK2. |
| PC-21376 |
MMT3-72
JAK inhibitor
|
MMT3-72 is a gastrointestinal locally-activating Janus kinase (JAK) inhibitor, readily converted to MMT3-72-M2 in the colon contents (JAK1 IC50=10.8 nM, JAK2 IC50=26.3 nM and TYK2 IC50=91.6 nM). |
| PC-21236 |
ABBV-712
TYK2-JH2 inhibitor
|
ABBV-712 is a potent, selective inhibitor of tyrosine kinase 2 (TYK2) with EC50 of 0.01 uM, binds and stabilizes the pseudokinase (JH2) domain of TYK2. |
| PC-21215 |
GDC-4379
JAK inhibitor
|
GDC-4379 is a potent, selective and inhaled JAK inhibitor with IC50 of 2 nM and 36 nM for JAK1 and JAK2 respectively, reduces FeNO and peripheral biomarkers of inflammation. |
| PC-20901 |
YLIU-5-162-1
JAK2 inhibitor
|
YLIU-4-105-1 is a novel type II JAK2 inhibitor, binds to JAK2 kinase domain (JH1), show potential for overcoming acquired resistance to ruxolitinib. |
| PC-20516 |
Zasocitinib
TYK2 inhibitor
|
Zasocitinib (TAK-279, NDI-034858) is a potent, selective and allosteric TYK2 inhibitor, targets TYK2 JH2 domain with binding KD of 3.8 pM. |
| PC-20143 |
CEE321
pan JAK inhibitor
|
CEE321 (CEE-321) is a potent, selective pan-JAK inhibitor with IC50 of 50, 48, 59 and 48 nM for JAK1, JAK2, JAK3 and TYK2, respectively. |
| PC-20060 |
Nimucitinib
JAK inhibitor
|
Nimucitinib is a potent, selective Janus kinase (JAK) inhibitor. |
| PC-49651 |
CPL409116
JAK/ROCK inhibitor
|
CPL409116 (CPL'116, CPL 409116) is a potent, competitive, dual JAK and ROCK inhibitor with IC50 of 0.95/5.36//0.87/110.6/106.7 nM for JAK1/JAK2/JAK3/ROCK1/ROCK2, respectively. |
